These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16936457)

  • 1. Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial.
    Imai K; Mori T; Izumoto H; Takabatake N; Kunieda T; Watanabe M
    Neurol Med Chir (Tokyo); 2006 Aug; 46(8):373-8; discussion 378. PubMed ID: 16936457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edaravone offers neuroprotection for acute diabetic stroke patients.
    Zheng J; Chen X
    Ir J Med Sci; 2016 Nov; 185(4):819-824. PubMed ID: 26597952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
    Yamaguchi T; Awano H; Matsuda H; Tanahashi N;
    J Stroke Cerebrovasc Dis; 2017 Apr; 26(4):756-765. PubMed ID: 27887792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction.
    Shinohara Y; Inoue S
    J Stroke Cerebrovasc Dis; 2013 Jul; 22(5):668-74. PubMed ID: 22622391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New modalities for the treatment of acute cardioembolic stroke.
    Uchiyama S
    Intern Med; 2006; 45(8):493-4. PubMed ID: 16702738
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study.
    Naritomi H; Moriwaki H; Metoki N; Nishimura H; Higashi Y; Yamamoto Y; Yuasa H; Oe H; Tanaka K; Saito K; Terayama Y; Oda T; Tanahashi N; Kondo H;
    Drugs R D; 2010; 10(3):155-63. PubMed ID: 20945946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry.
    Miyaji Y; Yoshimura S; Sakai N; Yamagami H; Egashira Y; Shirakawa M; Uchida K; Kageyama H; Tomogane Y
    Neurol Med Chir (Tokyo); 2015; 55(3):241-7. PubMed ID: 25739433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of edaravone in cardioembolic stroke.
    Inatomi Y; Takita T; Yonehara T; Fujioka S; Hashimoto Y; Hirano T; Uchino M
    Intern Med; 2006; 45(5):253-7. PubMed ID: 16595989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edaravone, a free radical scavenger, in the treatment of idiopathic sudden sensorineural hearing loss with profound hearing loss.
    Sano H; Kamijo T; Ino T; Okamoto M
    Auris Nasus Larynx; 2010 Feb; 37(1):42-6. PubMed ID: 19570630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy.
    Unno Y; Katayama M; Shimizu H
    Clin Drug Investig; 2010; 30(3):143-55. PubMed ID: 20155987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction.
    Ohta Y; Takamatsu K; Fukushima T; Ikegami S; Takeda I; Ota T; Goto K; Abe K
    Intern Med; 2009; 48(8):593-6. PubMed ID: 19367054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
    Takenaka K; Kato M; Yamauti K; Hayashi K
    J Stroke Cerebrovasc Dis; 2014; 23(10):2748-2752. PubMed ID: 25307430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction.
    Mishina M; Komaba Y; Kobayashi S; Tanaka N; Kominami S; Fukuchi T; Mizunari T; Hamamoto M; Teramoto A; Katayama Y
    Neurol Med Chir (Tokyo); 2005 Jul; 45(7):344-8; discussion 348. PubMed ID: 16041179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperbaric oxygen therapy in acute ischemic stroke: results of the Hyperbaric Oxygen in Acute Ischemic Stroke Trial Pilot Study.
    Rusyniak DE; Kirk MA; May JD; Kao LW; Brizendine EJ; Welch JL; Cordell WH; Alonso RJ;
    Stroke; 2003 Feb; 34(2):571-4. PubMed ID: 12574578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of effect of edaravone on ischemic stroke.
    Ishibashi A; Yoshitake Y; Adachi H
    Kurume Med J; 2013; 60(2):53-7. PubMed ID: 24291782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
    Green AR; Ashwood T
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):109-18. PubMed ID: 15857295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism.
    Mishina M; Komaba Y; Kobayashi S; Kominami S; Fukuchi T; Mizunari T; Teramoto A; Katayama Y
    Neurol Med Chir (Tokyo); 2008 Jul; 48(7):292-7. PubMed ID: 18654047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial).
    Shinohara Y; Saito I; Kobayashi S; Uchiyama S
    Cerebrovasc Dis; 2009; 27(5):485-92. PubMed ID: 19321945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
    Wada T; Yasunaga H; Inokuchi R; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N
    J Neurol Sci; 2014 Oct; 345(1-2):106-11. PubMed ID: 25085762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.